The expanding role of PET technology in the management of patients with colorectal cancer

Annals of Oncology

Volumn 18, Issue 11, 2007, Pages 1774-1781

  Herbertson, Rebecca A ^a   Lee, S T ^a,b   Tebbutt, N ^a,b   Scott, A M ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Colorectal cancer; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; IMATINIB; OXALIPLATIN; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; WATER O 15;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COLON ADENOMA; COLORECTAL CANCER; COLORECTAL SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HUMAN; HYPOXIA; IMAGE ANALYSIS; INCIDENTAL FINDING; ISOTOPE LABELING; LIVER METASTASIS; LUNG METASTASIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 35348820206     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm108     Document Type: Review

References (62)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
3. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321.
4. Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766.
5. Ruers TJ, Langenhoff BS, Neeleman N et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002; 20: 388-395.
6. Antoch G, Saoudi N, Kuehl H et al. Accuracy of whole-body dual-modality Fluorine-18-2-fluoro-2-deoxy-D-gluGose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22: 4357-4368.
7. Selzner M, Hany TF, Wildbrett P et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240: 1027-1034; discussion 1035-1026.
8. Votrubova J, Belohlavek O, Jaruskova M et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006; 33: 779-784.
9. Bar-Shalom R, Yefremov N, Guralnik L et al. Clinical performance of PET/ CT in evaluation of cancer: Additional value for diagnostic imaging and patent management. J Nucl Med 2003; 44: 1200-1209.
10. Hany TF, Steinert HC, Goerres GW et al. PET diagnostic accuracy: improvement with in-line PET-CT system: Initial results. Radiology 2002; 225: 575-581.
11. Park IJ, Kim HC, Yu CS et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006; 32: 941-947.
12. Furukawa H, Ikuma H, Seki A et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006; 55: 1007-1011.
13. Kantorova I, Lipska L, Belohlavek O et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: Comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003; 44: 1784-1788.
14. Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: The current role of MRI. Eur Radiol 2007; 17: 379-389.
15. Gearhart SL, Frassica D, Rosen R et al. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006; 13: 397-404.
16. Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
17. Wiering B, Krabbe PF, Jager GJ et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104: 2658-2670.
18. Bipat S, van Leeuwen MS, Comans EF et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology 2005; 237: 123-131.
19. Pessaux P, Lermite E, Brehant O et al. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93: 1-7.
20. Metcalfe MS, Mullin EJ, Maddern GJ. Choice of surveillance after hepatectomy for colorectal metastases. Arch Surg 2004; 139: 749-754.
21. Truant S, Huglo D, Hebbar M et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92: 362-369.
22. Strasberg SM, Dehdashti F, Siegel BA et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study. Ann Surg 2001; 233: 293-299.
23. Fernandez FG, Drebin JA, Linehan DC et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447; discussion 447-450.
24. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
25. Huebner RH, Park KC, Shepherd JE et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189.
26. Valk PE, Abella-Columna E, Haseman MK et al. Whole-body PET imaging with [18F]Fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134: 503-511.
27. Tanaka T, Kawai Y, Kanai M et al. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg 2002; 184: 433-436.
28. Lonneux M, Reffad AM, Detry R et al. FDG-PET improves the staging and selection of patents with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002; 29: 915-921.
29. Ciernik IF, Dizendorf E, Baumert BG et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 2003; 57: 853-863.
30. Dizendorf EV, Baumert BG, von Schulthess GK et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003; 44: 24-29.
31. Tanaka K, Adam R, Shimada H et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963-969.
32. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038-2048,
33. Findlay M, Young H, Cunningham D et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with-tumor response to fluorouracil. J Clin Oncol 1996; 14: 700-708:
34. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with collectal carcinoma. Q J Nucl Med 2003; 47: 8-13.
35. Goshen E, Davidson T, Zwas ST, Aderka D. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 2006; 5: 37-43.
36. Konski A, Hoffman J, Sigurdson E et al. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol 2005; 32: S63-S67.
37. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer 1999; 35: 1773-1782.
38. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006; 79: 32-36.
39. Weber W, Petersen V, Schmidt B et al, Positron emission tomography in nonsmall-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21: 2651-2657.
40. Shankar LK, Hoffman JM, Bacharach S et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: 1059-1066.
41. Gayed I, Vu T, Iyer R et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 17-21.
42. Langenhoff BS, Oyen WJ, Jager GJ et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: A prospective study. J Clin Oncol 2002; 20: 4453-4458.
43. de Geus-Oei LF, Wiering B, Krabbe PF et al. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Onool 2006; 17: 1650-1655.
44. Guillem JG, Moore HG, Akhurst T et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199: 1-7.
45. Kalff V, Duong C, Drummond EG et al. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 2006; 47: 14-22.
46. Francis DL, Freeman A, Visvikis D et al, In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52: 1602-1606.
47. Cook GJ. Oncological molecular imaging: Nuclear medicine techniques, Br J Radiol 2003; 76: S152-S158.
48. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24: 3282-3292.
49. Laking GR, West C, Buckley DL et al. Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol 2006; 58: 95-113.
50. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003; 29: 297-307.
51. Yoshmura H, Dhar DK, Kohno H et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: Correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004; 10: 8554-8560.
52. Cher LM, Murone C, Lawrentschuk N et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006; 47: 410-418.
53. Hicks RJ, Rischin D, Fisher R et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32: 1384-1391.
54. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 150-H20. J Nucl Med 2004; 45: 1851-1859.
55. van Kouwen MCA, Nagengast FM, Jansen JBMJ et al. 2-(18F)-Fluoro-2-Deoxy -D-Glucose Positron Emission Tomography Detects Clinical Relevant Adenomas of the Colon: A prospective study. J Clin Oncol 2005; 23: 3713-3717.
56. Kamel EM, Thumshim M, Truninger K et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45: 1804-1810.
57. Israel O, Yefremov N, Bar-Shalom R et al, PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: Incidence, localization patterns, and clinical significance. J Nucl Med 2005; 46: 758-762.
58. Services. CfMaM Medicare Expands Coverage of PET Scans. In Services UDoHaH ed), edition 2000.
59. Bradbury I, Facey K, Laking G, Sharp P. Investing in new technology: The PET experience. Br J Cancer 2003; 89: 224-227.
60. Zubeldia JM, Bednarczyk EM, Baker JG, Nabi HA. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases. Cancer Biother Radiopharm 2005; 20: 450-456.
61. Lejeune C, Bismuth MJ, Conroy T et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005; 46: 2020-2028,
62. Arulampalam T, Costa D, Visvikis D et al. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 2001; 28: 1758-1765.